Thermo Fisher Scientific (NYSE:TMO) Receives Outperform Rating from Raymond James Financial

Thermo Fisher Scientific (NYSE:TMO - Get Free Report)'s stock had its "outperform" rating restated by equities researchers at Raymond James Financial in a report issued on Thursday,Benzinga reports. They presently have a $535.00 price objective on the medical research company's stock, up from their previous price objective of $525.00. Raymond James Financial's price objective suggests a potential upside of 11.86% from the stock's current price.

Other research analysts have also issued research reports about the company. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Barclays raised their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday. Argus reduced their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Royal Bank Of Canada reduced their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $591.10.

Thermo Fisher Scientific Trading Up 2.5%

TMO stock traded up $11.58 during trading on Thursday, hitting $478.29. 4,419,891 shares of the company traded hands, compared to its average volume of 2,486,311. The firm has a market capitalization of $180.55 billion, a PE ratio of 28.11, a P/E/G ratio of 2.06 and a beta of 0.77. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a 50-day moving average of $411.01 and a 200-day moving average of $471.10. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The business's revenue was up 2.9% on a year-over-year basis. Analysts predict that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several institutional investors have recently modified their holdings of TMO. Revolve Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares in the last quarter. Port Capital LLC boosted its stake in shares of Thermo Fisher Scientific by 1.6% during the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after buying an additional 22 shares during the period. Clark Capital Management Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after buying an additional 23 shares during the period. Monograph Wealth Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after purchasing an additional 23 shares in the last quarter. Finally, Intergy Private Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after purchasing an additional 23 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.